

## ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF CO MMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1

of Sheet 1

Complete if Known				
Application Number	10/532,258			
Filing Date	April 21, 2005			
First Named Inventor	ventor J. K. Joung			
Art Unit	N/A			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	62031(51588)			

	U.S. PATENT DOCUMENTS						
Examiner initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where		
		Number-Kind Code <sup>2</sup> ( if known)			Relevant Passages or Relevant Figures Appear		
	AA	US-6,511,808	01/28/2003	Wolffe et al.			
	AB	US-6,503,717	01/07/2003	Case et al.			
	AC	US-6,492,117	12/10/2002	Choo et al.			
	AD	US-20020164575	11/07/2002	Case et al.			
	ΑE	US-20020160940	10/31/2002	Case et al.			
	AF	US-6,453,242	09/17/2002	Eisenberg et al.			
	AG	US-6,270,990	08/07/2001	Anderson et al.			
	AH	US-6,140,466	10/31/2000	Barbas, III et al.			
	Al	US-6,007,988	12/28/1999	Choo et al.			
	AJ	US-5,935,811	08/10/1999	Anderson et al.			
	AK	US-5,789,538	08/04/1998	Rebar et al.			

	FOREIGN PATENT DOCUMENTS						
Examiner Cite Initials* No.1		Foreign Patent Document	Publication	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY			T⁵	
	BA	EP 1,120,446	08/01/2001	Aventis Pharma S.A.			
	BB	WO 02/097092	12/05/2002	Garvan Inst. Of Medical Res.			
	BC	WO 96/27665	09/12/1996	California Institute of Tech.			
	BD	WO 99/41396	08/19/1999	Rhone-Poulenc Rorer S.A.			
	BE	WO 02/083929	10/24/2002	Clontech Labs, Inc.			
_	BF	WO 02/44326	06/06/2002	Stratagene			
	BG	WO 99/07389	02/18/1999	Lexicon Genetics Inc.			
	ВН	WO 02/26960	04/02/2002	Sangamo Biosciences, Inc.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	The indication of the second exponential catalog at a first page 12 to the property of the second catalog at t			
	CA	WOLFE et al. "Combining structure-based design with phage display to create new Cys₂His₂ Zinc finger dimers." Structure (2000) 8(7): 739-750			
	СВ	WANG et al. "Dimerization of zinc fingers mediated by peptides evolved in vitro from radiation sequences." Proc. Natl. Acad. Sci USA (1999) 96, 9568-9573			
	СС	SUGIURA "Natural and artificial zinc finger proteins." Riken Review (2001), 35: 102-103			
	CD	SEGAL et al. "Evaluation of a modular strategy for the construction of novel polydactyl zinc finger DNA-binding proteins." Biochemistry (2003) 42(7) 2137-2148			
	CE	CHONG et al. "REST: A mammalian silencer protein that restricts sodium channel gene expression to neurons." Cell (1995) 80, 949-957			
	CF	REBAR et al. Induction of angiogenesis in a mouse model using engineered transcription factors." Nature Medicine (2002) 8(12) 1427-1432			

Examiner	20 11 1	Date	00/00/0000
Signature	/Sue Liu/	Considered	03/26/2009